Capricor Therapeutics, Inc.
CAPR · NASDAQ
9/30/2025 | 6/30/2025 | 3/31/2025 | 12/31/2024 | |
|---|---|---|---|---|
| Revenue | $0 | $0 | $0 | $11,131 |
| % Growth | – | – | -100% | – |
| Cost of Goods Sold | $20,359 | $22,047 | $18,916 | $14,555 |
| Gross Profit | -$20,359 | -$22,047 | -$18,916 | -$3,424 |
| % Margin | – | – | – | -30.8% |
| R&D Expenses | $20,359 | $22,047 | $18,916 | $14,555 |
| G&A Expenses | $5,925 | $5,672 | $6,067 | $4,273 |
| SG&A Expenses | $5,925 | $5,672 | $6,067 | $4,273 |
| Sales & Mktg Exp. | $0 | $0 | $0 | $0 |
| Other Operating Expenses | -$20,359 | -$22,047 | -$18,916 | -$14,555 |
| Operating Expenses | $5,925 | $5,672 | $6,067 | $4,273 |
| Operating Income | -$26,284 | -$27,719 | -$24,983 | -$7,698 |
| % Margin | – | – | – | -69.2% |
| Other Income/Exp. Net | $1,713 | $1,808 | $591 | $581 |
| Pre-Tax Income | -$24,571 | -$25,911 | -$24,392 | -$7,117 |
| Tax Expense | $0 | $0 | $0 | $0 |
| Net Income | -$24,571 | -$25,911 | -$24,392 | -$7,117 |
| % Margin | – | – | – | -63.9% |
| EPS | -0.54 | -0.57 | -0.53 | -0.16 |
| % Growth | 5.3% | -7.5% | -231.3% | – |
| EPS Diluted | -0.54 | -0.57 | -0.53 | -0.16 |
| Weighted Avg Shares Out | 45,716 | 45,709 | 45,637 | 35,219 |
| Weighted Avg Shares Out Dil | 45,716 | 45,709 | 45,637 | 35,219 |
| Supplemental Information | – | – | – | – |
| Interest Income | $1,713 | $1,793 | $730 | $687 |
| Interest Expense | $0 | $0 | $0 | $0 |
| Depreciation & Amortization | $495 | $486 | $405 | $376 |
| EBITDA | -$24,076 | -$27,233 | -$24,577 | -$7,322 |
| % Margin | – | – | – | -65.8% |